Susumu Ishiguro1, Nabil A Alhakamy2, Deepthi Uppalapati1, Jennifer Delzeit1, Cory J Berkland3, Masaaki Tamura4. 1. Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506. 2. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047. 3. Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas 66047; Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66047. 4. Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas 66506. Electronic address: mtamura@vet.ksu.edu.
Abstract
To evaluate the potential of cell-penetrating peptide-based delivery of apoptosis-inducer gene in cancer therapy, a modified HIV-1 TAT peptide (dimerized TAT peptide, dTAT) was studied. The dTAT and plasmid DNA (pDNA) complexes (dTAT-pDNA) were condensed using calcium chloride (dTAT-pDNA-Ca2+). This simple nonviral formulation approach showed high levels of gene expression in vitro without any cytotoxicity. In mouse studies, a single intratracheal (IT) aerosol spray or 2 intravenous (IV) injections of the dTAT, apoptosis-inducer gene, angiotensin II type 2 receptor (AT2R), and Ca2+ complexes (dTAT-pAT2R-Ca2+) significantly attenuated the acutely growing mouse Lewis lung carcinoma allografts in mouse lungs. Furthermore, single IT (p = 0.054) and the combination of IT and IV (p < 0.05) administrations of dTAT-pAT2R-Ca2+ markedly attenuated slowly growing and relatively large-sized H358 human bronchioloalveolar carcinoma xenografts in mouse lungs. These results indicate that the dTAT-pDNA-Ca2+ effectively delivered the gene to cancer cells by either IT or IV administration although the local pulmonary delivery of the dTAT-pAT2R-Ca2+ showed more effective growth inhibition of orthotopic lung cancer grafts. Thus, the present study offers preclinical proof of concept that a dTAT-based nonviral gene delivery method via IT administration may be an effective lung cancer gene therapy.
To evaluate the potential of cell-penetrating peptide-based delivery of apoptosis-inducer gene in cancer therapn>y, a modified n>an class="Disease">HIV-1 TAT peptide (dimerized TAT peptide, dTAT) was studied. The dTAT and plasmid DNA (pDNA) complexes (dTAT-pDNA) were condensed using calcium chloride (dTAT-pDNA-Ca2+). This simple nonviral formulation approach showed high levels of gene expression in vitro without any cytotoxicity. In mouse studies, a single intratracheal (IT) aerosol spray or 2 intravenous (IV) injections of the dTAT, apoptosis-inducer gene, angiotensin II type 2 receptor (AT2R), and Ca2+ complexes (dTAT-pAT2R-Ca2+) significantly attenuated the acutely growing mouseLewis lung carcinoma allografts in mouse lungs. Furthermore, single IT (p = 0.054) and the combination of IT and IV (p < 0.05) administrations of dTAT-pAT2R-Ca2+ markedly attenuated slowly growing and relatively large-sized H358humanbronchioloalveolar carcinoma xenografts in mouse lungs. These results indicate that the dTAT-pDNA-Ca2+ effectively delivered the gene to cancer cells by either IT or IV administration although the local pulmonary delivery of the dTAT-pAT2R-Ca2+ showed more effective growth inhibition of orthotopic lung cancer grafts. Thus, the present study offers preclinical proof of concept that a dTAT-based nonviral gene delivery method via IT administration may be an effective lung cancer gene therapy.
Authors: A Eguchi; T Akuta; H Okuyama; T Senda; H Yokoi; H Inokuchi; S Fujita; T Hayakawa; K Takeda; M Hasegawa; M Nakanishi Journal: J Biol Chem Date: 2001-05-09 Impact factor: 5.157
Authors: Alexander H van Asbeck; Andrea Beyerle; Hesta McNeill; Petra H M Bovee-Geurts; Staffan Lindberg; Wouter P R Verdurmen; Mattias Hällbrink; Ulo Langel; Olaf Heidenreich; Roland Brock Journal: ACS Nano Date: 2013-04-30 Impact factor: 15.881